Penumbra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 07, 2024 at 04:05 pm EDT
Share
Penumbra, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 278.66 million compared to USD 241.4 million a year ago. Net income was USD 11 million compared to USD 8.56 million a year ago.
Basic earnings per share from continuing operations was USD 0.28 compared to USD 0.22 a year ago. Diluted earnings per share from continuing operations was USD 0.28 compared to USD 0.22 a year ago.
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.